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INTRODUCTION 
 Ischemic stroke is one of the major causes of morbidity and mortality in 
middle and late years of life. The incidence of stroke increases with age, this 
disability affects many people in their golden years. Stroke is the 3rd leading 
cause of death preceded only by cardiac disease and malignancy. 
Cerebrovascular accident is an abrupt onset of non-convulsive and focal 
necrologic defect.85% CVA caused by ischemia, out of which 20% of is 
constituted by cardio embolic stroke5. 
 Cardio embolic stroke is defined as non-lacunar stroke with presence of 
potential cardiac source in the absence of cerebrovascular diseases. It has an 
unfavourable outcome since it produces larger and more disabling stroke than 
other subtypes. Cardiac embolic stroke is largely preventable, rendering 
measures of  primary prevention valuable. Once the stroke has occurred the 
likelihood of recurrence is high, thus secondary prevention is also equally 
important32. 
 The availability of new diagnostic techniques especially transesophageal 
echocardiography (TEE) has allowed clinicians to identify cardiac source of 
embolism. TEE is a new application of endocardiography that allows high 
resolution imaging of atria, atrioventricular valves and aorta by inserting an 
ultrasonic  transducer in the esophagus10. 
 Recent studies suggest that transesophageal echocardiography may 
detect a potential source in upto 65%5 of patients with cerebral ischemic events 
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or systemic arterial embolism. This study was undertaken to compare the 
diagnostic yield of transesophageal echocardiography with transthoracic 
echocardiography in the detection of a cardiac source of embolism in patient 
with cerebral ischemic events under the age 45 yrs. 
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AIM OF STUDY 
1)  To compare the diagnostic yield of transesophageal 
echocardiography with transthoracic echocardiography in the 
detection of cardiac source of embolism in patients with cerebral 
ischemic events. 
2) To document intracardiac lesions which could have been the 
source of embolism for ischemic stroke. 
3) To evaluate the presence of clots in cardiac chambers. 
4)  To find out incidence of patent foramen ovale (PFO) in this study 
population. 
 . 
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REVIEW OF LITERATURE 
 Stroke or cerebrovascular accident25 is defined as abrupt onset of a  
neurologic deficit that is attributable to focal vascular cause. Thus the 
definition of stroke is clinical and laboratory studies including brain imaging 
are used to support the diagnosis. 
 Cerebral ischemia is caused by a reduction in blood flow that lasts 
longer than seconds. Neurological symptoms manifest within seconds because 
neurons lack glycogen, so energy failure is rapid. When blood flow recovers 
rapidly, brain tissue recovers fully and patients’ symptoms are only transient. 
This is called transient ischemic attack(TIA). 
 In TIA25, typically the neurological signs and symptoms last for 5 to 
15min but, by definition must last <24 hrs. 
 Stroke has occurred if neurological signs and symptoms last >24 hrs. i.e. 
cessation of blood flow for more than few minutes leads to infarction or death  
of brain tissue. 
 Generalized reduction in cerebral blood flow due to systemic 
hypotension usually produces syncope. If low cerebral blood flow persists for 
long duration, then infarction in border zones between major cerebral artery 
distribution develops. 
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 In more severe instances, global hypoxia-ischemia causes wide spread 
brain injury, the constellation of cognitive sequelae that ensues is hypoxic-
ischemic encephalopathy. 
 Stroke divided into ischemic and haemorrhagic out of which ischemic 
constitutes 85%; Haemorrhage form 15%25. 
 Atherothrombotic stroke-stroke produced by thrombosis of large 
intracranial vessel (0.5 to 3mm) in situ from atherosclerosis25. 
 Lacunar stroke-thrombotic occlusion of small intracranial vessels (30 to 
100 µm) which supply small volume brain, because they are end arteries. They 
result in stroke called lacunar stroke. Low flow stroke or transient ischemic 
attack if cardiac output or systemic B.P. reduced below some threshold. 
 Cerebral embolism refers to an obstruction of blood vessel in brain by 
an embolism originating any where in the circulatory system. Cardiogenic 
embolism is recognized increasingly as an important cause of stroke. 
Approximately 20% of all ischemic stroke are cardioembolic25. 
Cardio embolic stroke 
 The frequency of cardio embolic stroke in patients younger than 45 year 
age in much higher ranging from 23% to 36%37. 
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 New diagnostic techniques have allowed clinicians to better characterize 
well established sources of embolism and to discover other potential etiologies 
of cardio embolic stroke. 
 Cardio embolic stroke largely preventable warranting efforts at primary 
prevention for major risk cardio embolic sources. Once stroke due to cardio 
embolism has occurred, the likelihood of recurrence is relatively high for most 
cardio embolic sources and consequently secondary prevention is also 
important. 
Pathophysiology 
 No single mechanism is responsible for the development of cardiac 
emboli. The specific underlying cardiac diseases determines pathophysiology 
and natural history and hence each cardioembolic stroke must be considered 
separately. 
 Traditionally cardioembolic stroke have been regarded as severe and 
disabling. Undoubtedly large cortical infarction with hemorrhagic 
transformation are commonly of cardiac origin. These findings result from 
embolization of sufficiently large quantities of thrombus material or large 
vegetations, Constituting many of the cardio genic emboli. 
 Other cardiogenic emboli smaller; the associated hemispheric events 
may be transient or minor with small area of infarction or they may be retinal 
and present as transient monocular blindness or retinal infarction. 
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 The cerebral circulation absorbs 10% to 15% of cardiac output, carotid 
artery blood flow accounts for approximately 90% of total cerebral blood flow. 
The most commonly site of lodgement of cardiac emboli are main trunk and 
branches of middle cerebral artery, only 7% lodged in anterior cerebral artery, 
embolism into anterior  cerebral artery is rare17. 
 About 10% of cerebral emboli enter the vertebrobasilar circulation  
where they lodge in main  trunk or in one of the branches of posterior cerebral 
arteries. Once emboli have reached the cerebral circulation it causes ischemia, 
in contrast to thrombi, emboli are attached loosely to vascular walls and this 
commonly migrate distally. When this occurs reperfusion causes blood to leak 
into surrounding infarcted tissue. This explain the more frequent association of 
haemorrhagic infarction with cardiogenic embolism than with other causes of 
ischemic stroke, which occurs from 12 to 36 hr after embolization and often 
asymptomatic. 
In the great majority of patients haemorrhagic transformation does not 
cause clinical worsening because the bleeding involves necrotic tissue. 
Frequency 
 14-31% of ischemic stroke are cardio embolic depends on criteria and 
study design32. 
 Consistent geographic variation is not evident and frequency is likely 
similar throughout if adjusted for mean population age. 
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Mortality/morbidity 
 In general cardioembolic strokes have a worst prognosis and produce 
larger and more disabling strokes than other ischemic stroke subtypes because 
emboli of large size from cardiac chambers. 
 Sex : Female to male ratio increase with age 
Age : Bimodal higher in young less than 50 years and very old 
>75 yrs. 
History 
 Although not sufficiently sensitive or specific to establish the diagnosis, 
several clinical features help to distinguish cardiogenic embolism from other 
mechanism. 
 Decreased level of consciousness at onset of stroke 
 Sudden onset of symptoms and signs that are maximal at onset. 
 Rapid recovery from major hemispheric deficit due to reperfusion of 
brain with early lysis of the embolus. 
 Onset of symptoms after a valsalva provoking activity (enhancing 
right to left shunt in patient with patent foramen ovale). 
 Symptoms reflecting involvement of different vascular territories of 
brain. 
 Certain neurologic syndromes suggest embolism often cardio 
embolism as their cause. They are 
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I. In the middle cerebral artery territory 
a. Frontal opercular with facial weakness and severe aphasia or 
dysarthria. 
b.  The brachial or hand plegia syndrome which the arm or hand is 
paralysed with or without cortical sensory  abnormalities. 
c.   Broca's or wernicke's aphasia alone 
d.    Left visual neglect-non dominant parietal lobe. 
II. Posterior cerebral artery embolus-Sudden hemianopia 
III. Anterior cerebral artery territory: Sudden weakness of foot and 
shoulder.  
IV. Sudden sleepiness and inability to look up associated with bilateral 
ptosis suggest an embolism to the top of basilar artery specifically to the 
artery of percheron. 
 Seizures at time of stroke occurs in 3 to 5% of infarctions most often 
associated embolic rather than thrombosis25. 
 Cardiogenic embolic (especially from chamber) do not often affect 
deep penetrating arteries as a lacunar syndrome, small cardiogenic 
emboli from valvular source can obstruct the small penetrating 
arteries causing subcortical lacunar infarcts. 
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Physical 
1. Evidence of cardiac atrial dysrhythmias (eg, atrial fibrillation, sick 
sinus syndrome). 
2. Presence of cardiac murmurs (eg, mitral stenosis, calcific aortic 
stenosis) 
3. Signs of congestive heart failure (eg, after acute myocardial 
infarction, nonischemic cardiomyopathies). 
4. Concomitant diseases (eg, systemic lupus erythematosus and 
Libman-Sachs endocarditis, neoplasia, marantic endocarditis). 
5. Concomitant signs of systemic embolism 
6. The probability of finding such signs in patients with suspected 
cardioembolic stroke is low (approximately 1%) for most 
cardioembolic sources. 
7. The diagnosis of cardioembolic stroke is based on the triad32 (1) 
identification of a potential cardioembolic source, (2) absence of 
other likely causes of stroke, and (3) supportive clinical features 
described above. 
Causes 
 More than 20 specific cardiac disorders have been implicated in leading 
to brain embolism. Dividing cardiac sources of embolic into major-and minor-
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risk categories is clinically useful (see below). Major-risk sources carry a 
relatively high risk of initial and recurrent stroke convincingly linked to a 
cardioembolic mechanism. When a major-risk cardioembolic source is present, 
efforts at primary prevention of stroke usually are indicated; stroke in patients 
with any of these causes is most often cardioembolic. Minor-risk sources are 
frequent in the general population, and the associated risk of initial and 
recurrent stroke with any of these conditions is either low or uncertain. When a 
minor-risk cardioembolic source is present in a patient with cerebral ischemia, 
the etiologic role must be viewed with skepticism and considered in the context 
of other diagnostic information. 
 Source of cardioembolic embolism include the following: Asterix (*) 
indicates a major-risk source; dagger (†) indicates emboli originating in the 
venous circulation or right heart that cause ischemic stroke via abnormal 
cardiac or pulmonary shunting around the pulmonary capillary bed. 
Valvular disease 
• Rheumatic mitral stenosis* 
• Prosthetic valves* 
• Calcific aortic stenosis 
• Bicuspid aortic valves 
• Mitral annulus calcification 
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• Nonbacterial thrombotic (marantic) endocarditis* associated with 
malignancies and prothrombic states 
• Myxomatous mitral valvulopathy with prolapse 
• Infective endocarditis* 
• Inflammatory valvulitis (ie, Libman-Sacks endocarditis, Behcet 
disease, syphilis) 
• Lambl excrescences and/or strands 
Left ventricular thrombi 
• Ischemic heart disease* 
• Acute myocardial infarction* 
• Left ventricular akinesis or aneurysm* 
• Idiopathic hypertrophic subaortic stenosis 
• Trauma (myocardial contusion) 
• Ventricular non compaction 
• Nonischemic cardiomyopathies* (eg, idiopathic dilating viral 
myocarditis associated, echinococcal, peripartum, amyloid-
associated, hypereosinophilia syndrome-associated, rheumatic 
myocarditis-associated, sarcoidosis-related, neuromuscular 
disorder-associated, alcoholism-related, catecholamine-induced, 
Chagas disease-associated, doxorubicin-induced, mitoxantrone-
related, crack cocaine-related, cardiac oxalosis-associated). 
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• Left ventricular thrombi associated with prothrombotic states* 
• Antiphospholipid antibodies 
• Diffuse intravascular coagulation 
• Essential thrombocythemia and myeloproliferative diseases 
Left atrial thrombi 
• Arrhythmias 
• Atrial fibrillation* 
• Sick sinus syndrome/atrial asystole* 
• Atrial flutter* 
• Atrial septal aneurysms 
• Chiari network 
Cardiac tumours 
• Atrial myxoma 
• Cardiac sarcoma 
• Endocardial fibroelastoma 
• Metastatic disease 
Paradoxical emboli† 
• Atrial septal defects 
• PFO 
• Ventricular septal defects 
• Pulmonary arteriovenous fistulas 
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Miscellaneous 
• Postcardiac catheterization 
• Post valvuloplasty 
• Esophageal-atrial fistula 
Atrial fibrillation: The leading cause of cardioembolic stroke, especially 
in elderly individuals, atrial fibrillation is percent in approximately 1% of the 
US population and in approximately 5% of those older than 70 years32. 
Formerly associated with rheumatic valvular disease, it now is related 
most frequently to hypertension and ischemic heart disease (ie, nonvalvular 
atrial fibrillation). 
Both paroxysmal and chronic atrial fibrillation are associated with 
increased risk of stroke. Stasis secondary to decreased contractility of the left 
atrium leading to thrombus formation in its appendage is the postulated 
mechanism. 
In a autopsy study of 642 patients with atrial fibrillation of various 
causes, a left atrial thrombus was found in 15.8% as opposed to 1.7% in 642 
age of sex matched controls1. 
Left ventricular thrombus was encountered in 1% of patient with atrial 
fibrillation. Cerebral infarction occurred in 32.2% of the patients with atrial 
fibrillation and in only 11% of the controls1. 
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The frequency cerebral infarction increased with duration of fibrillation 
the most common causes of atrial fibrillation were rheumatic and ischemic 
heart diseases. Presence of atrial fibrillation in acute stroke associated with 
worsened prognosis at 1 to 6 months6. 
Non valvular atrial fibrillation is a major cardioembolic stroke as well as 
of massive cerebral infarctions. 
Transesophageal echocardiography is more sensitive than trans thoracic 
echocardiography for visualization of left atrium and its appendage5. 
Not all atrial fibrillation associated strokes are cardio embolic, in 
individual cases excluding other potential causes of stroke such as intrinsic 
cerebrovascular disease or aortic atheroma. 
The annual rate of stroke in atrial fibrillation varies widely from 0.5-
12% per year depending on prevalence and combination of risk factors; thus, 
risk stratification is the first necessary step in choosing the best preventive 
therapy. Several clinical risk stratification schemes have been proposed to 
identify atrial fibrillation at high, moderate, or low risk; this is crucial for 
selecting which patients would benefit most and least from anticoagulation. 
The CHADS2 (ie, CHF, hypertension, age >75 y, diabetes, stroke or TIA) 
classification scheme is the most validated and accurately stratifies stroke risk 
(Gage, 200113A; Go, 200319; Gage, 2004)18. 
Two randomized controlled trials have demonstrated that a strategy 
aimed at restoring (and maintaining) sinus rhythm neither improves the 
survival rate nor reduces the risk of stroke. In the atrial fibrillation follow-up 
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investigation of Rhythm Management (AFFIRM) study28, 4060 patients aged 
65 years or older whose atrial fibrillation was likely to be recurrent and who 
were at risk for stroke were randomized to a strategy of rhythm control 
(cardioversion to sinus rhythm, plus a drug(s) to maintain sinus rhythm) versus 
a strategy of rate control (in which no attempt was made to restore or maintain 
normal sinus rhythm). An insignificant trend toward increased mortality was 
noted in the rate control group and importantly, no evidence suggested that the 
rhythm control strategy protected patients from stroke. 
The AFFIRM study (and similar findings from the smaller Rate Control 
Versus Electrical Cardioversion [Race]21 trial) has led to the development of 
consensus guidelines advocating a rate-control strategy for most patients with 
atrial fibrillation. 
Adjusted-dose warfarin (international normalized ratio [INR] 2-3) is 
associated with a 60% reduction in stroke incidence, while the efficacy of 
aspirin is modest (20%). Low-dose warfarin (INR<1.5), either alone or 
combined with aspirin, is not effective, highlighting the marginal benefit of 
warfarin when anticoagulation is not carefully regulated. Incidence of 
intracerebral hemorrhage, the most dreaded complication of warfarin therapy, 
is estimated to be 0.5% per year among elderly patients with atrial fibrillation  
and is sensitive to blood pressure control. When warfarin is given to elderly 
patients with atrial fibrillation, hypertension must be managed aggressively 
(Hart, 2005)22. 
Recommendations for primary and secondary prevention based on risk 
factor stratification are presented in (Table 3). 
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In the setting of acute stroke secondary to atrial fibrillation, 
anticoagulation with heparin has not demonstrated more benefit than early 
treatment with aspirin. Initiate aspirin early, followed by warfarin as soon as 
the patient is medically stable; discontinue aspirin after therapeutic 
anticoagulation is achieved (Hart, 2003). 
In short, warfarin has demonstrated high efficacy in stroke prevention in 
patients with this common arrhythmia. Disadvantages include the increased 
risk of hemorrhagic complications and the need for close INR monitoring in 
these patients; thus, consider patient preferences along with risk stratification 
and absolute risk reduction offered by this therapy. Alternative approaches (eg, 
surgical ablation of atrial appendage) are the subjects of ongoing clinical 
investigation. 
Ximelagatran, a new oral thrombin inhibitor, is comparable to adjusted-
dose warfarin for stroke prevention in patients with atrial fibrillation. The 
Stroke Prevention Using an Oral Direct Thrombin Inhibitor in Patients with 
Atrial Fibrillation (SPORTIF)29 III and V clinical trials recently demonstrated 
that treatment of atrial fibrillation with ximelagatran twice daily is equivalent 
to adjusted-dose warfarin when considering stroke and major hemorrhage, but 
INR monitoring and dosage adjustments are unnecessary. However, potential 
liver toxicity led to disapproval by the US Food and Drug Administration 
(FDA) in late 2004. 
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Stroke rates by CHADS2 score* 
CHADS2 Score Risk Stroke Rate Per Year 
0 Low 1% 
1 Low 1.5% 
2 Moderate 2.5% 
3 High 5% 
> Very high >7% 
 
*Score determined by: CHF, hypertension, age>75, and/or diabetes=1 
point; stroke or TIA=2 points. 
Table : 3 
 
Prevention of stroke in nonvalvular atrial fibrillation-recommendations 
 
Prevention Risk group Recommended 
prevention 
Range of 
Management 
Lone AF†, 
<60 y 
None Aspirin 325 mg/d‡ 
Low risk Aspirin 325 mg/d‡ Warfarin, INR 1.6-3.0, 
Moderate 
risk 
Warfarin, INR 1.6-3.0, 
or aspirin 325 mg/d 
-- 
High risk, 
>75 y 
Warfarin, INR 2.0-3.0 Aspirin if warfarin 
contraindicated 
Primary 
prevention* 
High risk 
>75 y 
Warfarin, INR 1.6-2.5 Aspirin if warfarin 
contraindicated 
Secondary 
prevention 
 Warfarin, INR 2.0-3.0 Aspirin if warfarin 
contraindicated 
 
*See table 2 for current CHADS2 stratification schemes. 
†AF indicates atrial fibrillation. 
‡ Lower doses of aspirin are probably equally efficacious; the value of aspirin 
combined with clopidogrel 75 mg/d is being tested in a large randomized trial. 
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Sick sinus syndrome (SSS) 
 Any form of sinus node depression such as marked sins bradycardia 
(<50 beats/min), sinus arrest or sino atrial block. 
 The SSS occurs throughout life, but is more common in older patients. 
 It may be associated with IHD, cardiomyopathy and neuromuscular 
disease but is frequently idiopathic or degenerative in origin. 
 The clinical manifestation are mainly those provided by transient global 
ischemia (Light headedness and syncope). However patients with SSS are at 
high risk for stroke, which is usually massive in presumably cardioembolic in 
origin. 
 The only effective treatment for SSS is pacemaker implantation, but the 
stroke rate is still high after pacing. 
Valvular heart disease 
Rheumatic heart disease (RHD) 
 Clinical embolic events occur in about 20% patients with RHD9. 
 Embolism usually complicates mitral stenosis or mixed stenosis 
regurgitation. Whereas pure mitral regurgitation or aortic disease less 
frequently results in embolism9,11. 
 20 
Mitral stenosis 
 Mitral stenosis is most often of rheumatic origin, left atrial thrombi form 
in a large number of affected patients, particularly in the presence of atrial 
fibrillation or cardiac failure. 
 Left atrial thrombus is present in 15% to 17% of patients at autopsy, 
regardless of whether or not there has been a H/o of embolism9. 
 Thrombi may develop in patients with only Mild mitral stenosis,  
explaining why embolism may be a presenting symptoms of mitral stenosis. 
 In patients with mitral stenosis the annual incidence of all symptomatic 
emboli is about 4% more than half are cerebral but many asymptomatic 
systemic emboli and occasional asymptomatic cerebral embolic are found at 
postmortem9. 
 Recurrent embolism is common (30% to 75%) usually within 6 to 12 
months of sentinal event and the presence of atrial fibrillation increases the risk 
embolism four fold. The risk of embolism also increases with increasing 
duration of mitral stenosis39. 
 Spontaneous echo contrast is a dynamic smoke like signal that is 
detected by TEE in patients with stasis of blood in left atrium 42 patients with 
mitral stenosis or atrial fibrillation spontaneous echo contrast compared patient 
without spontaneous echo contrast, showed spontaneous echo contrast is highly 
associated with previous stroke or peripheral embolism in patient with atrial 
fibrillation or mitral stenosis7. 
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 Embolisation of left atrial thrombi account for >45% of cardiogenic 
emboli, left atrial thrombi are most often associated with atrial fibrillation or 
rheumatic mitral stenosis.  
 The sensitivity of transthoracic echo cardiography for the detection of 
left atrial thrombi is only 39-63%33 in contrast TEE offers detailed visualization 
of both body of left atrium and left atrial appendage5. 
 Careful discrimination of thrombi from left atrial pectinate muscles, as 
well as familiarity of multi lobed appearance of the normal left atrial 
appendage can be better appreciated with multiplane TEE5. 
 Long term anticoagulation recommended for prophylaxis in patients 
with rheumatic mitral stenosis and coexistent atrial fibrillation, as combination 
of both carries a 17 fold increase in stroke risk compared with matched 
controls38. 
 Then embolic and recurrent emboli rates are notably decreased with 
long term anticoagulation although long term therapy is not totally protective. 
Mitral regurgitation 
 Mitral regurgitation most commonly results from mitral valve prolapse 
or papillary muscle dysfunction association with ischemic or rheumatic heart 
disease. 
 When severe the mitral regurgitation produces an ulcerated "Jet lesion" 
on atrial endocardial surface, left atrial thrombus may form there, this occurs in 
some what less than 10% of patients and almost invariably in the presence of 
atrial fibrillation36. 
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 Thrombo embolism is a recognised complication of mitral regurgitation. 
The incidence is low even though atrial fibrillation is a common 
accompaniment particularly late in course. 
Aortic stenosis 
 Isolated aortic stenosis is mainly caused by calcification of valve cusps, 
a process observed predominately in elderly people. Most patients seen with 
cerebral embolism have had multivalvular rheumatic diseases or coexistent 
infective endocarditis27. 
 Introduction of echo, doppler and catheterization it has become evident 
that calcific aortic stenosis may be responsible for more cerebrovascular events  
than recognized. 
 Calcific micro emboli can be detected in the retinal artery is 
asymptomatic patients possibly reflecting the fact that most cerebral emboli are 
asymptomatic. Clinical embolism often follows invasive cardiac procedure 
(catheterization). 
Because of the calcific nature of embolic anticoagulation is not recommended. 
Mitral annular calcification 
 This is associated with advancing age, hypertension and atherosclerosis 
and it is rarely embolic source15. 
 23 
Mitral valve prolapse 
 Mitral valve prolapse a common finding in young, carries a benign 
course for most individuals and is an unusual cause of stroke among those 
harboring mitral valve prolapse. It should the considered as the underlying 
cause for stroke only, if extensive search for other causes has been negative. 
 Prophylactic treatment is unwarranted in individuals with asymptomatic 
mitral valve prolapse in patients where cerebral ischemia is attributed to mitral 
valve prolapse aspirin therapy is recommended on empirical grounds and only 
in treatment failures ,when further events occur, should anticoagulants be used. 
Idiopathic hyper trophic subaortic stenosis (IHSS) 
 Idiopathic hyper trophic subaortic stenosis is felt to carry a low risk of 
embolism. Atrial fibrillation is often associated in there into do have presumed 
cardioembolic source16. 
Prosthetic valves 
 Thromboembolism remains a major cause of morbidity and mortality 
complicating prosthetic valve implantation. The majority of thrombo embolic 
events are cerebrovascular. There are many kinds of mechanical valves all of 
which require life long anticoagulation therapy to prevent thrombo embolism. 
 Even such treatment, patients with mechanical valves experience further 
embolic events at a rate comparable to non anticoagulated patients with  
bioprosthetic valves. 
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 The rate of embolism in patients with mechanical valve averages 3% to 
4% /yr. In aortic position the rate estimated to be lower averaging 1.2% to 
2.2% / yr13. 
 When bioprosthetic valve is inserted long term anticoagulation is not 
recommended when other risk factors are absent. 
 Permanent anticoagulation (INR 2.5-3.5) is mandatory for prosthetic 
valves .For bioprosthetic valves aspirin usually is recommended unless the 
patient has atrial fibrillation or evidence of atrial stasis. 
 Prosthetic valve endocarditis is another complication and a potential 
source of cerebral embolism, incidence 2.4%/yr. In patient with prosthetic 
valves, occurrence of neurologic complications is higher with mechanical valve  
mitral in position26. 
Evaluation of mechanical and bioprosthetic valves for valvular function 
and exclusion of thrombi or vegetation is best performed by TEE. 
Patient with mechanical prosthesis who present with evidence of 
systemic embolisation are generally assumed to have prosthetic valve thrombi 
especially when INR is low. 
Acute myocardial infarction 
 The incidence of stroke often AMI is approximately 2% in the first 3 
months. Acute myocardial infarction with mural thrombus on TTE have been 
recognized as predictive of stroke. Anticoagulation INR 2-3 is recommended in 
these patients in the 1st 3 months, while antiplatelet therapy is advocated long 
term. 
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 The presence of congestive cardiac failure after Acute myocardial 
infarction usually dictates treatment with warfarin indefinitely. Low cardiac 
output failure (EF<30%) is also considered a high risk situation, as is the 
presence of a left ventricular aneurysm on echo. 
 Anticoagulation therapy should be discontinued after 3 to 6 months over 
if left ventricular thrombi persists.  Routine anticoagulation has not been 
recommended if left ventricular thrombi are detected in aneurysmal sac at a 
time remote from Acute myocardial infarction14. 
 Instead long term anticoagulation has been recommended only in 
patients with cerebral insults attributed to persistent left ventricular thrombi. 
The recommended treatment policy for patients with acute transmural  
myocardial infarction includes use of high dose of heparin, even if 
thrombolytic therapy is given.  Echo should be performed 5 to 7 days later to 
detect left ventricular thrombi if no thrombus or wall motion abnormalities, 
heparin should be discontinued. 
 The line of TTE with higher frequency transducers  (5.0 MHz) really 
identifies or excludes left ventricular thrombi in most patients, among patients 
with poor apical windows or those whom TTE data are equivocal, TEE is a 
certainly reasonable alternative for identifying these thrombi5. 
Dilated cardiomyopathies 
 Arrhythmias are common, either as nonsustained ventricular tachycardia 
or chronic atrial fibrillation, which develop 20 to 30% of patients. Thus 
arrhythmias and high prevalence of left ventricular thrombi that are found in 
dilated cardiomyopathies are believed to be the underlying cause for stroke and 
other embolic complication in these patients. 
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 Echo detects the presence of thrombi in 11% to 58% of patients with 
idiopathic dilated cardiomyopathy, yet it is not helpful for detection of at high 
risk for stroke as there is no correlation has been found between the detection 
of thrombi and presence of emboli. 
Infective endocarditis 
 Of patients with infective endocarditis, 20% experience an embolic 
stroke, staphylococcus aureus is the agent producing highest stroke rate, mitral 
valve endocarditis is the most common source of emboli. Antibiotic therapy 
reduces embolic potential when administered in the acute phase. 
Anticoagulation is contraindicated because of unacceptable rates of 
hemorrhagic stroke. 
 In patients prosthetic valve endocarditis the risk of thromboembolism is 
greater than the risk of ICH, this anticoagulation usually recommended if no 
evidence of haemorrhage is found on CT scanning 24-48 hrs after the stroke, 
consensus is to start anticoagulation 7 days after the stroke-the role of 
antiplatelet therapy has not been established. 
Non bacterial thrombotic endocarditis 
 Associated with variety of malignancies like carcinoma lung, pancreas 
and prostate non bacterial thrombotic endocarditis also has been reported in 
patients with severe diseases such as septicaemia and extensive burns. Mitral 
and aortic valves are affected most commonly and embolic stroke is frequent, it 
is mainly found in normal cardiac valves. 
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 A prothrombotic state has been postulated as the precursor of emboli 
development. The vegetations in NBTE are usually small and are composed of 
platelet and fibrin deposits. 
 Treatment is directed toward control of underlying disease and heparin 
(I-V in Acute stage, subcutaneous in the O-P setting) is advocated for stroke 
prevention. Warfarin failed to show any benefit. 
Cardiac myxoma 
 Most common primary heart tumour . very rare cause of stroke. 
 The tumour is usually benign and originates  in left atrium in 75% cases, 
primarily diagnosed in young and middle aged adults. It is usually located in 
the fossa ovalis. It may present with either constitutional, cardiac obstructive or 
embolic symptoms alone or in combination. Embolic manifestation occur in 20 
to 45% of patients sometimes as the first symptoms. Although emboli may 
lodge in any vascular system CNS is involved in upto 50% cases. Embolic 
material consists of mainly myxomatous tissue. 
Neurologic manifestation, consist mainly of acute focal neurological 
deficit that may be the initial presentation of disease. Most can be detected by 
TTE, rarely it can be detected only by TEE especially small and multiple as in 
familial myxoma syndrome. Surgical excision is the treatment of choice. 
Paradoxical embolism 
 The name implies that an embolus originating in the venous system 
finds its way to lodge on the arterial tree and implies the existence of right to 
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left shunts possible shunts incriminated in pathophysiology of paradoxical 
embolism include patent foramen ovale, atrial septal defect and pulmonary A-
V fistula. 
PFO (patent foramen ovale) 
 Hemodynamically insignificant interatrial communication is present in 
over 25% of the adult population. 
 Because stroke occurs more frequently in older population with only 3% 
of cerebral infarction occurring in patients <40 yrs of age, The no. of stroke 
patient with PFO >40 yrs of age is much larger than in the younger patients. 
Several studies reported the association of PFO with cryptogenic stroke in 
older population. However this has not been in seen in all studies. 
 Therefore, although the association between cryptogenic stroke and PFO 
is established among the younger population, it is not clearly established in the 
older population. 
 Webster et al.10A performed contrast echocardiography in 40 patients 
with stroke or TIA all aged under 40 yrs, and 40 age and sex matched controls, 
A PFO was found in 50% of patients with cryptogenic stroke. Transthoracic 
echocardiography and transesophageal echocardiography with saline contrast 
are widely used to detect PFO.  
 PFO is judged to be present if any microbubble in seen in left side 
chambers with in 3 cardiac cycles from the maximum right atrial Opacification 
after injection of agitated saline is prepared by mixing 0.5 to 1 ml of air with 10 
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ml of NS through two syringes the peripheral I-V line34. Injection is performed 
with and without valsalva maneuver, cough during injection increase the 
sensitivity for detecting PFO over that achieved by valsalva maneuver. 
 TEE contrast study is the most sensitive diagnostic test available for 
detecting a PFO followed by TCD and transthoracic contrast studies. 
 In recent PFO in cryptogenic stroke study (PICSS) it also has been 
shown that large PFO's were significantly more prevalent among Cryptogenic 
stroke patients compared with those with known cause of stroke. Additionally 
stroke patients with larger PFO have brain imaging finding suggestive of an 
embolic phenomenon. 
Deep vein thrombosis (DVT) 
 Stolleberger et al35. study demonstrated that patients with PFO who have 
paradoxical embolization may harbor the source of embolism in lower 
extremities. The frequency of DVT in cryptogenic stroke patients with PFO is 
not clearly defined although the most recent series indicates that is increased. 
Atrial septal aneurysm (ASA) 
 ASA is a redundancy of interatrial septum detected most commonly by 
TTE or TEE studies.  It is detected significantly more frequently using TEE 
study compared to TTE study. On TTE study defined as 15mm protrusion or 
excursion of interatrial septum with base of 15mm, in TEE it is >10mm. 
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 The prevalence of ASA in patients with cerebral systemic embolic 
events is high and reaches 73%. It is well known that ASA is associated with 
PFO. It can be seen approximately 60% patients with ASA also have PFO. 
 When ASA associated with PFO others source of embolism 
anticoagulation usually recommended. Management is controversial because of 
lack of diagnostic certainty and absence of randomised evidence. Antiplatelet 
therapy is often advocated initially and warfarin is recommended  empirically. 
If stroke recurs during antiplatelet therapy or if prothrombic diathesis 
predisposing to recurrent DVT. 
SURGICAL CLOSURE OF PFO  
The no. of patient in each one of the series is small for both 
percutaneous and surgical closure. Also the selection criteria vary among 
studies patient included them the young. Consequently the efficacy of 
percutaneous or surgical PFO closure remains undefined and is best reserved 
for young patients not able to undergo medical therapy. 
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MATERIALS AND METHODS 
Stroke patients admitted in medical wards Govt. General Hospital 
during the period of June 2005 to March 2006, were selected for this study. 
INCLUSION CRITERIA   
1. Patients with or without cardiac disease  below the age 45 yrs.. 
 2. Patient without any known  risk factors for thrombotic stroke. 
Exclusion criteria 
1) Age >45 yrs. 
2) Patient with known risk factors for Atherothrombotic stroke like  
diabetes mellitus, systemic hypertension, smoking. 
3) CT suggestive of haemorrhage. 
 Only inpatients were included in series to ensure that investigation, 
treatment and follow up of cases are done properly and efficiently 
Detailed history was taken from patients who where conscious and not 
aphasic. In  unconscious patients, history was taken from a reliable informant. 
A thorough cardiovascular and neurological examination were carried 
out. After relevant investigation patients with hypertension,  diabetes mellitus 
hyperlipidemia were excluded from the study. 
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METHODOLOGY 
 Patients with stroke less than 45 yrs were submitted to CT scan. If scan 
showed infarction, haemorrhagic transformation or multiple infarcts they were 
included in the study, pure haemorrhagic stroke were not included. Both 
transthoracic echocardiography & transesophageal echocardiography were 
done for all patients, on the same day by cardiologist who  has adequate 
training. Standard parasternal and apical views were obtained using Aloka 
ultrasonic 2000 interfaced with 5MHZ transducer. Intra venous saline contrast 
was not given during transthoracic echocardiography. 
 Transesophageal colour doppler echocardiography was performed after 
obtaining informed Consent, by using multiplane transesophageal  
echocardiography 5MHZ transducer interfaced  with Aloka  2000. 
 A complete multiplane transesophageal echocardiography done in all 
patients, 14 patients were given saline contrast during transesophageal 
echocardiography. 
 The following echocardiographic abnormalities were considered a 
possible cardiac source of embolism. Left atrial or left ventricular thrombi, left 
atrial spontaneous echocontrast12, mitral stenosis, myxomatous degeneration of 
mitral valve with prolapse3, severe mitral annular calcification, atrial septal 
defect, patent foramen ovale, atrial septal aneurysm, left ventricular aneurysm 
or apical hypokinesia, aortic or mitral vegetation, atrial myxoma, moderate and 
severe globular left ventricular hypokinesia and prosthetic heart valve. 
 33 
STATISTICAL ANALYSIS 
 Qualitative data was expressed in frequencies with their percentage. 
 Quantitative data was expressed in mean standard deviation (SD). 
 Qualitative data was analysed (Sex, TTE, TEE) to compare the 
difference between those with clinical evidence of heart disease and those with 
no clinical evidence of heart disease by Pearson Chi-square test and Yates 
corrected chi-square test. Then odds ratio was given with 95% confidence 
interval. 
 Quantitative data (age) was analysed using student t-test to compare the 
significant difference between those with clinical evidence of heart disease and 
those with no clinical evidence of heart disease. 
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OBSERVATION AND RESULTS                                                    
35 patients with ischemic stroke below the age of 45 yrs were assessed 
clinically and biochemically . Three  of these patients had diabetes, 2 could not 
swallow and were not included in the study.  A total of 30 patients were 
included in the study  
SEX DISTRIBUTION 
Sex No. of patients Percentage 
Male 17 56% 
Female 13 44% 
 
AGE DISTRIBUTION 
Age Male Female Total Percentage 
12-20 1 2 3 10% 
21-30 2 3 5 17% 
31-40 12 5 17 56% 
41-45 2 3 5 17% 
 
 Mean age with maximum incidence is 31-40 (56%); minimum incidence 
was in the younger age group 12-20 (10%). 
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CLINICAL FEATURES 
Based upon side of involvement and severity of weakness 
 Right Left 
Hemiplegia 8 9 
Hemiparesis 6 6 
Posterior circulation 1 - 
 
 Aphasia was found in 12 (40%) cases. All of them had right hemiplegia. 
These 30 patients were divided into two groups based on presence or 
absence of clinical evidence of heart disease.  
GROUP I  - 16 cases 
PATIENTS WITH CLINICAL EVIDENCE OF HEART DISEASE 
Age Male Female Total Percentage 
<20 - 2 2 12% 
21-30 1 2 3 19% 
31-40 3 5 8 50% 
41-45 - 3 3 19% 
 
 There is female predominance in Group I since rheumatic mitral stenosis 
is more common in females. 
 Both the patients less than 20 yrs had prosthetic valves in mitral  
position. 
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Group II (14 cases) 
PATIENTS WITH NO CLINICAL EVIDENCE OF HEART DISEASE 
Age Male Female Total Percentage 
<20 1 - 1 8% 
21-30 1 1 2 14% 
31-40 9 - 9 64% 
41-45 2 - 2 14% 
 
 Here there is a slight male preponderance and the age group affected 
maximum is 31-40. 
STATISTICAL ANLAYSIS OF AGE IN GROUP I & GROUP II 
 N Mean 
age 
SD t-test 
With clinical evidence of 
heart disease 16 32.87 8.53 
With  no clinical evidence 
of heart disease 14 34.50 6.77 
E = 0.57 
P = 0.58 
Not significant 
 
 In both Group I and Group II mean age was similar ,which is not 
statistically  significant. 
 37 
STATISTICAL ANALYSIS OF SEX IN GROUP I & II 
 Clinical evidence 
of heart disease 
No clinical evidence 
of heart disease 
Male 4 13 
Female 12 1 
 
Pearson chi-square X2 = 14.0  P = 0.001 
 When comparing Group I & Group II there is obvious sex difference, 
which is also statistically significant, more males in Group I, more females in 
Group II. 
 Out of 30 patients , 16 had clinical evidence of heart disease. 
Cardiac Abnormality Number Percentage 
Rheumatic heart disease        11 69% 
Coronary artery disease 2 12.5% 
Prosthetic valve 3 18.5% 
 
 This table shows rheumatic heart disease accounts for 11 cases (69%)of 
patients with heart disease. Still  rheumatic heart disease forms the major cause 
of cardioembolic stroke in developing countries. 
 Three patients had prosthetic valve in mitral position . They were on oral 
anticoagulant therapy. 
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 In all the 30 patients subjected to transthoracic echocardiography  the 
findings are: 
Rhematic heart disease 11 
Mitral valve prolapse  2 
Coronary heart disease 3 
RHD with Left atrial clot 1 
RHD with Left atrial spontaneous echocontrast 2 
Prosthetic valve 3 
 
Rheumatic heart disease 
 Based on associated valve involvement and rhythm disturbance the 
patients with rheumatic heart disease were further subdivided as shown below. 
 
 Isolated mitral valve involvement  5              
 
Mitral and Aortic valve involvement 5  
 
Mitral valve involvement with Left atrial clot   - 1 
Mitral, Aortic valve and Tricuspid valve    - 1 
[4with AF] 
[1without AF] 
[3with AF] 
[2without AF] 
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 In the study isolated mitral stenosis constitutes the predominant lesion 
which accounts for 45% (5 cases); in association with aortic valve involvement 
forms another 45% (5 cases); associated with tricuspid valve involvement in 
10% (1 case). 
 Mitral stenosis is commonly associated with atrial fibrillation, which                                          
increases  risk of stroke by 17fold  compared with matched controls. 
 Only one case of rheumatic mitral stenosis had left atrial clot. In the 
remaining it is likely that fresh clots could have been discharged to systemic 
circulation. 
Mitral valve prolapse 
 In 30 cases 2 (6%) cases were identified to have mitral valve prolapse by 
transthoracic echocardiography. Both the patients had no clinical evidence of 
heart disease i.e. they belonged to Group II.  
Coronary artery disease 
Two male patients below 40 yrs had ECG showing old inferior wall 
myocardial infarction. In both cases Transthoracic echocardiography showed 
hypokinetic inferior and posterior segments. One had associated left ventricular 
aneurysm with an adherent thrombus.  
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Based on Transoesohageal echocardiography 
 30 patients  subjected to transoesophageal echocardiography  findings 
are 
Cardiac abnormality Detected by TEE 
Left atrial spontaneous echo contrast 8 
Left atrial appendage clot 3 
Left ventricular clot 1 
Myoxmatous mitral valve with mitral regurgitation 2 
Patent foramen ovale 1 
Atrial septal aneurysm  1 
Complex aortic atheroma - 
Prosthetic valve dysfunction 1 
 
 When comparing with transthoracic echocardiography transesophageal 
echocardiography additionally detected 6 cases of left atrial spontaneous echo 
contrast, 2 cases of left atrial appendage clot, one case of patent foramen ovale 
with atrial  septal aneurysm, one case of prosthetic valve  dysfunction. 
Transesophageal echocardiography versus transthoracic 
echocardiography 
 The heart disease of patients in Group I was confirmed by transthoracic 
echocardiography. Transthoracic echocardiography also detected 1 left atrial 
clot in a patient with rheumatic mitral stenosis, left atrial auto contrast in 2 
cases; left ventricular thrombus in 1 case. Totally it detected cardiac source of 
embolism in 4 cases (25%). 
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Transesophageal echocardiography revealed a potential cardiac source 
of embolism in 13patients (81%) i.e. it confirmed transthoracic 
echocardiography findings in 4 cases. And TEE detected an additional of 9 
cases (56%) ,with left atrial spontaneous echo contrast in 6 cases (37 %), 2 
more cases of rheumatic mitral stenosis showed left atrial thrombus, left atrial 
appendage being better visualised in transesophageal echocardiography. In one 
case of prosthetic valve, mild dysfunction was visualised in transesophageal 
echocardiography, out of 16 cases; 7 cases of RHD had atrial fibrillation and 
one patient with prosthetic valve had atrial fibrillation. 
 Group II cases, no clinical evidence of heart disease transthoracic 
echocardiography detected 2 cases (14%) of mitral valve prolapse which is also 
confirmed by transesophageal echocardiography and additionally detected 2 
STROKE
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16 14
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(14%) abnormalities ; one had patent foramen ovale detected by right to left 
shunting diagnosed by contrast studies and color flow imaging. This case also 
had associated atrial sepal aneurysm, which is an common accompaniment 
patent foramen ovale. 
Statistical analysis 
 Detection rates of TTE statistically compared in those patients with 
clinical evidence of heart disease and in those with no clinical evidence of heart 
disease. 
TTE 
 Cardiac 
abnormalities 
present 
Cardiac 
abnormalities 
Not present 
Clinical evidence of heart disease 4 (25%) 12 
No clinical evidence of heart disease 2 (14%) 12 
  
Pearson chi-square X2 Yates = 0.08  P = 0.78 
 It shows that difference is statistically not significant. However in 
patients with clinical evidence of heart disease, it is able to detect one out of 
four cases; whereas in no clinical evidence of heart disease one out of six cases. 
TEE 
 Similarly detection rates of TEE statistically compared, with clinical 
evidence of heart disease in those with no clinical evidence of heart disease 
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 Cardiac 
abnormalities 
present 
Cardiac 
abnormalities 
Not present 
Clinical evidence of heart disease 13 (81%) 3 
No clinical evidence of heart disease 4 (29%) 10 
 
Pearson chi-square X2 Yates = 6.43 P = 0.01 Odds ratio (O.R)=11(2-92) 
 It shows that difference is statistically significant, observed according to 
Yates corrected chi-square test. And also it shows that those with clinical 
evidence of heart disease TEE is able to detect 11 times more than those with 
no clinical evidence of heart disease. 
TTE Vs TEE in patients with clinical evidence of heart disease. 
 Cardiac abnormalities 
present 
Cardiac abnormalities Not 
present 
TTE 4 12 
TEE 13 3 
 
Pearson chi-square X2 Yates = 8.03 P = 0.01 Odds ratio (O.R)=13 (2-108) 
 Comparing TEE against TTE in patients with clinical evidence of heart 
disease, cardiac abnormalities detected by TEE was 81% (13/16) patients 
against TTE which detected 25% (4/16) patients. It is statistically significant.  
TTE Vs TEE in patients with no clinical evidence of heart disease. 
 Cardiac abnormalities 
present 
Cardiac abnormalities Not 
present 
TTE 2 12 
TEE 4 10 
Pearson chi-square X2 Yates = 0.21 P = 0.65 Not significant 
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 Comparing TEE against TTE in patients with no clinical evidence of 
heart disease, cardiac abnormalities detected by TEE was 25% (4/14) patients 
against TTE which detected 14% (2/14) patients. This is not statistically 
significant.  
Thoracic aorta was carefully examined in multiplane transesophageal 
echocardiography in all patient, no protruding thrombus was identified, none of 
them had atrial fibrillation in this group. 
 Out of 30 cases 17 (56%) patients ultimately had cardiac source of 
embolism identified by mean transesophageal echocardiography 22 (73%) in 
sinus rhythm and 8 had (27%) atrial fibrillation. Out of eight, seven patients 
with atrial fibrillation with potential cardial source of embolism detected. The 
most common cardiac source identified was spontaneous echocontrast. This 
abnormality is better detected by transesophageal echocardiography. 
Cardiac abnormality Detected by 
TTE 
Detected by 
TEE 
Total 
Left atrial spontaneous echo 
contrast 
2 8 8 
Left atrial appendage clot 1 3 3 
Left ventricular clot 1 1 1 
Myoxmatous mitral valve with 
mitral regurgitation 
2 2 2 
Patent foramen ovale - 1 1 
Atrial septal aneurysm  - 1 1 
Complex aortic atheroma - - - 
Prosthetic valve dysfunction - 1 1 
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 Left atrial spontaneous echo contrast was detected by TTE  in  14% 
patients (2/16)with clinical evidence of heart disease, whereas TEE detected 
the same in 50%(8/16)patients. So detection rate of TEE against TTE is 
statistically significant (X2 = 5.24, P=0.02, OR = 7 (1-63) according to Pearson 
chi-square test and hence TEE is 7 times more useful  compared to TTE. 
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DISCUSSION 
 This study demonstrates the increased yield of transesophageal 
echocardiography in the detection of a potential cardiac source of embolism in 
stroke patients compared with transthoracic echocardiography. 
In our study transthoracic echocardiography revealed a potential cardiac 
source of embolism in 25% (4 patients) all of whom had clinical evidence of 
heart diseases and 14% (2 patients) who had no clinical evidence of heart 
disease. 
In addition to the yield by transthoracic echocardiography, 
transesophageal echocardiography revealed a potential source of embolism in 
56% (9 cases). In patients with clinical evidence of heart disease, cardiac 
abnormalities additionally detected by transesophageal echocardiography are 2 
cases of LA appendage clot, 6 cases of left atrial spontaneous echo contrast and 
one case of prosthetic valve dysfunction. In patients with no clinical evidence 
of heart disease, transesophageal echocardiography detected one case of patent 
foramen ovale with atrial septal aneurysm. 
 This is in keeping with previous studies30,42,22. Pop et al.30 found  5 (9%) 
of 53 patients with  recent TIA or stroke and without clinical cardiac 
abnormalities had abnormal TEE . Six (32%) of 19 patients with clinically 
suspected cardiac source of embolism had both a positive TEE and a positive 
TTE. The lower yield of TEE in that study may be due to lack of color flow 
imaging and contrast studies to detect intracardiac shunts. The proportion of 
patients with AF is not mentioned and was likely to be lower than in our study 
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Zenker et al.40 found that 9 (45%) of 20 patients with a cerebral  
ischemic events under the age of 45 yrs and a normal TTE, TEE showed 
pathological findings which consisted mainly mitral valve prolapse, atrial 
septal defect and atrial aneurysms. 
In the European multicenter study reported by Daniel et al2. 479 
patients with unexplained arterial embolism were studied with TTE and TEE. 
The majority of these patients had a cerebral ischemic event. Potential source 
of arterial source of embolism were detected by TTE in 176 (37%) of 479 
patients and by TEE in 310 (65%) of 479 patients. TEE identified mitral valve 
prolapse, patent foramen ovale, left atrial and atrial appendage thrombi, 
spontaneous echocontrast, atrial septal aneurysm and valvular vegetation 
significantly more frequently than transthoracic echocardiography. The yield of 
TEE was higher in that study because of the inclusion of patient with peripheral 
arterial embolism. 
Black et al24. 100 patients with cerebral ischemic event or peripheral 
arterial embolism  (63), before percutaneous Balloon dilatation of mitral valve 
(23), or before electrical cardioversion (14) were studied with TTE and TEE. 
TEE showed potential embolic sources in 36/53 (68%) patients with AF 
compared with 9/47 (19%) with sinus rhythm. TEE identified left atrial 
spontaneous echocontrast, left ventricular spontaneous echocontrast, mitral 
valve prosthesis thrombus, mitral valve prolapse and pronounced aortic 
atheroma significantly and more frequently than TTE, which helped in 
avoidance of Balloon dilatation of mitral valve in some patients. 
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Cujec et al10. compared diagnostic yields of TEE and TTE in detection 
of cardiac source of embolism. 63 patients with TIA or stroke underwent both 
procedures, TTE revealed potential source of cardiac embolism in 14% (9) of 
the patients with clinical evidence of heart disease, TEE revealed a potential 
cardiac source of embolism in 41% (26) of the patients, 27% (7) of these 
patients has no clinical cardiovascular abnormalities. Abnormality detected 
only by TEE included atrial septal aneurysm, PFO, left atrial appendage 
thrombus and myxomatous mitral valve. Patient identified cardiac source of 
embolism more frequently in AF and had larger left atrium. 
 
 TTE TEE 
Clinical evidence heart disease 
6/19 (32%) 
6/19 (32%) 
Pope et al. 
Normal heart  5/53 (9%) 
Daniel et al. 176/479 (37%) 310/474 (65%) 
Black et al. 
 36/53 (68%) 
9/47 (19%) 
Normal 7/39 (18%) 
Cujec et al. Clinical evidence heart disease 
9/20 (38%) 
19/24 (79%) 
Normal 2/14 (14%) 4/14 (25%) 
Present study Clinical evidence heart disease 
4/16 (25%) 
13/16 (81%) 
 
 Our present study correlates well with Cujec et al. both for no clinical 
evidence of heart disease (X2=1.54, P=0.21; Not significant) and clinical 
evidence of heart disease (X2=0.03, P=0.87; Not significant); because there is 
no statistical significant difference. 
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In our study TTE revealed only mitral valve prolapse in patients without 
clinical evidence of cardiac disease. This is in keeping with previous reports. In 
25% of the patients with clinical evidence of heart disease, a potential source of 
cardiac embolism was detected by TTE. The incidence of transthoracic echo 
cardiographic abnormalities in stroke patients varies from 4 to 47%8,20 
depending on the criteria used. A definitive source of embolism such as 
valvular vegetation or thrombus or myxoma are detected in very few patients. 
Patient with clinical evidence of cardiac disease frequently have 
potential cardiac source of embolism detected by TEE. Although its diagnostic 
yield in patients without obvious heart disease is low, TEE may have 
therapeutic impact and should be performed in young patients or those with 
multiple stroke  or systemic embolism. 
TEE is superior to TTE for the detection of left atrial thrombus, patent 
foramen ovale, atrial septal aneurysm, left atrial spontaneous echocontrast and 
myxomatous degeneration of mitral valve, associated with mitral valve 
prolapse. All of these cardiac abnormalities may be a source of embolism. 
Atrial fibrillation is a well known contributor to stroke. In our study, out 
of 8 patients in seven with atrial fibrillation transesophageal echo cardiogram 
revealed cardiac source of embolism. Belder et al.4 found that patients in atrial 
fibrillation with left atrial spontaneous echocontrast are four times more likely 
to have suffered thromboembolic event than patients in AF without 
spontaneous echocontrast . Three of the patients with left atrial spontaneous 
echocontrast had left atrial appendage thrombus. In patients with AF  
underlying structural heart disease is ruled out by TEE, then it is more likely to 
be "lone AF". 
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One of the major limitations of this study is the lack of age matched 
control group of volunteers without strokes. The cardiac abnormalities 
associated with systemic embolism can also be detected in persons who do not 
have strokes, although the prevalence of all these abnormalities is higher in 
patients with strokes. Only stroke cases were taken for the study. Patients with 
TIA & normal CT brain  were excluded. Saline contrast studies were not 
performed during TTE. The patient with PFO was detected by color flow 
imaging and contrast study only by TEE. Transthoracic contrast echo is 
insensitive and non specific for the detection of right to left shunting through 
patent foramen ovale. 
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CONCLUSION 
 The prevalence and pattern of cardiac disorder in 30 ischemic stroke 
patient was studied and analysed. 
1. Transesophageal echocardiography is of great value in patients 
with clinical evidence of heart disease. In patients with no clinical 
evidence of heart disease transesophageal echocardiography has 
proved to be useful to detect lesions in small percentage of 
patients without clinical evidence of heart disease which are not 
even detected by transthoracic echocardiography. Hence 
transesophageal echocardiography is superior to transthoracic 
echocardiography in the detection of cardiac source of embolism 
in patients with cerebral ischemic event. 
Since this present study involves only small no. of patients 
usefulness of TEE in patients with no clinical evidence heart 
disease needs more studies involving large number of patients. 
2. In this study Rheumatic heart disease stands as the foremost 
source of embolism (36%). Among this mitral valve involvement 
was found in almost all cases. The highest yield in TEE was 
associated with atrial fibrillation than without atrial fibrillation. 
Mitral valve prolapse accounted for 6% of cases of ischemic 
stroke. Coronary artery disease is an uncommon source of 
embolism in patients less than 45 yrs. Prosthetic valve is also an 
important source of embolism . 
3. Clots in cardiac chambers was detected only in 10% of cases. 
4. Patent foramen ovale was detected in 3% of cases. 
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SUMMARY 
To compare the diagnostic yield of transesophageal echocardiography and 
transthoracic echocardiography in the detection of potential cardiac source of 
embolism in young stroke patients, 30 patients with stroke underwent both 
procedures. Transthoracic echocardiography revealed a potential cardiac source 
of embolism in 25% (4 patients) all of whom had clinical evidence of heart 
diseases and 14% (2 patients) who had no clinical evidence of heart disease. 
In addition to the yield by transthoracic echocardiography, 
transesophageal echocardiography revealed a potential source of embolism in 
56% (9 cases). In patients with clinical evidence of heart disease, cardiac 
abnormalities additionally detected by transesophageal echocardiography are 2 
cases of LA appendage clot, 6 cases of left atrial spontaneous echo contrast and 
one case of prosthetic valve dysfunction (which is statistically significant). In 
patients with no clinical evidence of heart disease, transesophageal 
echocardiography detected one case of patent foramen ovale with atrial septal 
aneurysm. Thus transesophageal echocardiography is more sensitive than 
transthoracic echocardiography in detection of potential cardiac source of 
embolism. 
 
PROFORMA 
CARDIAC SOURCE OF EMBOLISM IN YOUNG STROKE 
Name   Age   Sex   I.P.No. 
D.O.A.  D.O.D.  Unit 
Complaints     Duration 
Weakness of limb  Rt/Lt 
Aphasia 
Headache 
Vomiting 
Seizures 
Loss of consciousness 
Previous stroke 
Others 
Past history 
DM 
Hypertension 
Smoking 
Prev heart disease 
Oral anti coagulant 
Hyper cholesterolemia 
Apla/Prothrombotic states 
Alcoholism 
Collagen vascular disease 
OC Pills 
Others 
TIA 
General Examination 
Anemia 
Cyanosis 
Clubbing 
Lctrus 
Lymphadenopathy 
Pedal oedema 
Pulse 
Blood pressure 
R.R. 
CVS 
RS 
ABDOMEN 
CNS 
INVESTIGATIONS 
Hb  TC  DC  ESR 
SUGAR UREA CREAT  Na  K  Cl 
VDRL HIV 
Sr. LIPID PROFILE 
RF  CRP  ANA 
OTHERS 
 
ECG 
Rate  axis  AF 
QRS  RVH  LVH  Crochetage 
OTHERS 
 
Chest X-ray 
 
ECHO 
CD No  Echo No. 
TTE     TEE 
LA spont echocontrast  LA spontaneous echo contrast 
LA thrombus    LA Thrombus 
LVH     Complex aortic atheroma >5mm 
LV apical thrombus   Patent foramen ovale 
Valvular heart disease  Atrial Septal aneurysm 
MS     Valvular vegetations & intra cardiac masses 
AS     Mitral valve prolapse 
MR 
TR 
Mitral valve calcification 
 
PHT 
LV wall motion abnormalities N/AB 
Hypokinetic Akinetic 
LV Aneurysm 
LV wall scaring 
LV systolic function 
Mitral valve prolapse 
 
CT BRAIN     MRI BRAIN 
ABBREVIATIONS 
 AF - Atrial fibrillation 
 AR - Aortic regurgitation 
 ASA - Atrial septal aneurysm 
 AS - Aortic stenosis 
 AMI - Acute myocardial infarction 
 CMC - Closed mitral commissurotomy 
 CT - Computed tomography 
 CVA - Cerebrovascular accident 
 IHD - Ischemic heart disease 
 IWMI - Inferior wall  myocardial infarction 
 LVH - Left ventricular hypertrophy 
 LAE - Left atrial enlargement 
 LA - Left atrium/al 
 LV - Left ventricle/ventricular 
 MS - Mitral stenosis 
 MVP - Mitral valve prolapse 
 MCA - Middle cerebral artery 
 MR - Mitral regurgitation 
 NSR - Normal sinus rhythm 
 PFO - Patent foramen ovale 
 RBBB - Right bundle branch block 
 RVH - Right ventricular hypertrophy 
 RVR - Rapid ventricular response 
 RHD - Rheumatic heart disease 
 TTE - Transthoracic echo cardiography 
 TEE - Transesophageal echo cardiography 
 WNL - Within normal limits 
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TEE showing PFO with atrial septal aneurysm TEE showing opacification of  right atrium and saline 
contrast cross over to left atrium
 TEE bicaval view color Doppler showing flow across the
inter atrial septum TEE apical four chamber view showing LA spontaneous
echo contrast with LA appendage clot
 CT brain (plain) axial section showing right MCA territory 
infarct with hemorrhagic transformation   CT brain (plain) axial section showing right MCA territory
infarct with hemorrhagic transformation  
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LA spontaneous
echo contrast
LA appendage clot LV clot MVP with MR PFO ASA Prosthetic valve
dysfunction
Echo findings
TTE Vs TEE
 PERCUTANEOUS DILATATIONAL TRACHEOSTOMY GROUP 
 
 
Sl. 
No. 
Name, Age, Sex, IP 
No. Ward 
No. of days 
intubated 
Diagnosis  Duration of
procedure 
in min. 
Intraoperative complications Post-operative Complication Follow up 
     Lowest
 SaO
 Major 
Bleed2
Minor 
Bleed 
False 
Passage
Resistant 
to 
Insertion 
Transient 
hypoten. 
Transient 
hypoxia 
Major 
bleed
Minor 
bleed
Stomal 
infec. 
Pneumo.
thorax 
Death Sub. 
emphy.
TE 
fistula
TA 
fistula
Deccanu
lated 
Tra. 
Stenosis 
1. Narayanan 36/M 
633301 N1 wd. 
7                   Extradural haemorrhage 12 94 - - Yes - - - - - - - - - - - Yes -
2. Sekar 19/M  
635070 N1 wd. 
12 Lt temparo parietal 
contusion 
9                  90 - - - - - - - - - - - - - - - -
3. Selvakumar 22/M 
635428 N1 wd.  
6                    Subdural haemorrhage 8 94 - - - - - Yes - - - - - - - - - -
4. Neela 60/F  
637664 IMCU 
9                    Brainstem infarct 10 96 - - - - - - - - - - - - - - - -
5. Parasuraman 56/M 
637519 IMCU 
12 Type II DM with 
Necrotising pneumonia 
12                  95 - - Yes - - - - - - - - - - - - -
6. Raju 18/M  
635419 IMCU 
11 Guillain barre syndrome 13 99 - Yes Yes - - - - - - - - - - - Yes - 
7. Manjunathan 45/M 
638471, N1 Wd 
6                    Extradural haematoma
craniotomy done 
8 90 - - - - - Yes - - - - - - - - - -
8. Sakthivelu 58/M 
639162 IMCU 
10 Type 2 DM with pulm HT 10 92 - - - - - - - - - - - - - - - - 
9. Karvan 34/M 643857 
IMCU 
7                    Brainstem stroke 11 96 - - - Yes - - - - - - - - - - - -
10. Peter 46/M 668254 
IMCU 
8 HT with DM with Hypoxic 
encephalopathy 
7                  93 - - - - - - - - - - - - - - - -
11. Mr.Vasudevan 45/M 
674125 N1 Wd 
7                    Left parietal SDH 10 94 - - - - Yes - - - - - - - - - - -
12. Mr. Krishnakumar 6 Rt. temparo parietal 10 98 - - - - - - - - - - - - - - - - 
Sl. 
No. 
Name, Age, Sex, IP 
No. Ward 
No. of days 
intubated 
Diagnosis Duration of 
procedure 
in min. 
Intraoperative complications Post-operative Complication Follow up 
     Lowest 
 SaO2
Major 
Bleed
Minor 
Bleed 
False 
Passage
Resistant 
to 
Insertion 
Transient 
hypoten. 
Transient 
hypoxia 
Major 
bleed
Minor 
bleed
Stomal 
infec. 
Pneumo.
thorax 
Death Sub. 
emphy.
TE 
fistula
TA 
fistula
Deccanu
lated 
Tra. 
Stenosis 
30/M 678599 N1 Wd contusion 
13. Rajan 42/M  
678486 N1 Wd 
10                    Brainstem hemorrage 8 97 - - - - Yes - - - - - - - - - - -
14. Thangaraj 24/M 
680101 IMCU 
8 OPC poisoning                12 96 - Yes - - - - - - - - - Yes - - - -
15. Arumaidoss 30/M 
680181 IMCU 
6                    Guillain Barre syndrome 6 91 - - - - - - - - - - - Yes - - - -
16. Venkatesan 70/M 
680108 N1 Wd 
5                    Intracerebral
hemorrahage 
10 92 - - - - - - - - - - - - - - - -
17. Ganesh 24/M  
680204 N1 Wd 
7 SDH & EDH Operated 7 94 - - - - Yes - - - - - - - - - - - 
18. Hemavaty 21/F 
673344 IMCU 
7                    OPC Poisioning 10 90 - - - - - - - - - - - - - - Yes -
19. Jayalakshmi 40/F  
680291 N1 Wd 
7 CP Angle tumour  
operated 
8                  90 - - - - - - - - Yes - - - - - - -
20. Selvam 30/M  
680201 IMCU 
8                    OPC poisoning 15 98 - - Yes - - - - - - - - - - - - -
21. Chandrasekar 45/M 
672282 IMCU 
7 RTA with multiple injuries 8   94 - - - - - - - Yes - - - - - - - - 
22. Balakrishnan 35/M 
680095 N1 Wd 
7                    Intracerebral hemorrage 10 92 - - - - - - - - - - - - - - - -
23. Natarajan 48/M 
679575 N1 Wd 
11 RTA with multiple 
contusion brain 
7                  90 - - - - - Yes - - - - - - - - - -
24. Sampathkumar 34/M 
680120 N1 Wd 
9 RTA Rt. frontoparietal 
contusion 
9                  90 - - - - - - - - - - - - - - - -
25. Murugan 37/M 680185 6 RTA with Temporal 10 97 - - - - - - - - - - - - - - - - 
Sl. 
No. 
Name, Age, Sex, IP 
No. Ward 
No. of days 
intubated 
Diagnosis Duration of 
procedure 
in min. 
Intraoperative complications Post-operative Complication Follow up 
     Lowest 
 SaO2
Major 
Bleed
Minor 
Bleed 
False 
Passage
Resistant 
to 
Insertion 
Transient 
hypoten. 
Transient 
hypoxia 
Major 
bleed
Minor 
bleed
Stomal 
infec. 
Pneumo.
thorax 
Death Sub. 
emphy.
TE 
fistula
TA 
fistula
Deccanu
lated 
Tra. 
Stenosis 
N1 Wd Depressed fracture  
 
 STANDARD OPERATIVE TRACHEOSTOMY GROUP 
 
 
Sl. 
No. 
Name, Age, Sex, IP 
No. Ward 
No. of 
days 
intubated
Diagnosis  Duration of
procedure 
in min. 
Intraoperative compucations Post-operative Compucation Follow up 
     Lowest
SaO
  Major 
Bleed2
Minor 
Bleed 
False 
Passage
Resistance 
to Insertion
Trasient 
hypoten. 
Trasient 
hypoxia
Major 
bleed
Minor 
bleed
Stomal 
infec. 
Pneumo.
thorax 
Death Sub. 
emphy.
TE 
fistula
TA 
fistula
Deccanu
lated 
Tra. 
Stenosis 
1. Sakunthala 23/F 
632663 IMCU 
7                    Encephalitis 20 98 - - - - - Yes - - - - - - - - - -
2. Anbudurai 22/M 
632603 N1 Wd 
5 RTA with Frontoparietal 
contusion 
25                 94 - Yes - - - - - - Yes - - - - - - -
3. Raju 18/M  
635419 IMCU 
10                    Transverse myelitis 22 96 - - - - - - - Yes - - - - - - Yes -
4. Vimala 42/F  
636205 IMCU 
8 COPD with respiratory 
failure 
25                 90 Yes - - - - - - - - - - - - - - -
5. Kamalam 62/F 
637427 N1 Wd 
6 RTA with extradural 
hemorrhage 
25                 97 - Yes - - - - - - - - - - - - Yes Yes
6. Mohammed Ali 21/M 
636508 N1 Wd 
9 RTA with intracerebral 
hemorrhage 
20                  92 - - - - - - - - - - - - - - - -
7. Venkatesan 22/M 
638997 IMCU 
7 RHD with pulmonary 
edema 
30               97 Yes - - - - - - Yes - - - - - - Yes -
8. Manikandan 25/M 
639022 N1 Wd 
7 RTA with occipital 
contusion 
18                  95 - - - - - Yes - - - - - - - - Yes -
9. Kesavaraj 39/M 
638839 N1 Wd 
6 RTA with frontal 
contusion with 
intracerebral 
hemorrhage 
24                  98 - - - - - - - - - - - - - - - -
10. Govindhammal 28/F 
639812 IMCU 
7 RTA with Brainstem 
dysfunction 
26               90 - Yes - - - - - Yes Yes - - - - - - -
11. Thulasi 50/F 
639377 N1 Wd 
12 RTA Rt Fronto parietal 
contusion 
30               88 Yes - - - - - - Yes - - - - - - - -
Sl. 
No. 
Name, Age, Sex, IP 
No. Ward 
No. of 
days 
intubated
Diagnosis Duration of 
procedure 
in min. 
Intraoperative compucations Post-operative Compucation Follow up 
     Lowest  
SaO2
Major 
Bleed
Minor 
Bleed 
False 
Passage
Resistance 
to Insertion
Trasient 
hypoten. 
Trasient 
hypoxia
Major 
bleed
Minor 
bleed
Stomal 
infec. 
Pneumo.
thorax 
Death Sub. 
emphy.
TE 
fistula
TA 
fistula
Deccanu
lated 
Tra. 
Stenosis 
12. Iqbal 25/M  
640216 IMCU 
6                    OPC poisoning 28 99 - - - - - - - Yes - - - - - - Yes -
13. Sampath 51/M 
662702 IMCU 
8 CVA with Rt 
intracerebral 
hemorrhage  
25                  94 - Yes - - - - - Yes - - - - - - -
14. Kiran 22/M 
664939 N1 Wd 
8 RTA with Lt frontal 
compound depressed 
fracture 
20                  97 - - - - Yes - - - - - - Yes - - - -
15. Nayagam 50/F 
665978 N1 Wd 
5                   RTA Lt
Temparoparietal SDH 
26 90 - Yes - - - - - - - - - - - - - -
16. Balasubramanian 
54/M 6665104,IMCU 
7 RTA with multiple 
injuries 
22                  92 - - - - - - - - Yes - - - - - Yes -
17. Balakrishnan 52/M 
680811 N1 Wd 
5 RTA with extradural 
hemorrhage 
18                  97 - - - - - - - - - - - - - - - -
18. Muthammal 50/F 
681212 N1 Wd 
7                  RTA intracerebral
hemorrhage 
26 99 - Yes - - - - Yes - - - - - - - - -
19. Ramzan Bevi 50/F 
682227 IMCU 
10                    Myaesthenia gravis 25 90 - - - - Yes - - - Yes - - - - - Yes -
20. Gurunathan 50/M 
681354 N1 Wd 
7 RTA with subdural 
hemorrage 
28                 92 - Yes - - - - - - - - - Yes - - - -
21. Paneerselvam 55/M 
683795 N1 Wd 
7 RTA with Lt temparo 
parietal contusion 
25                  92 - - - - - - - - - - - - - - Yes -
22. Ashok Kumar 22/M 
684474 N1 Wd 
8 RTA Rt fronto parietal 
contusion 
25                  94 - - - - - - - - Yes - - - - - - -
23. Murugesan 28/M 
684810 N1 Wd 
6 RTA Rt fronto parietal 
contusion 
20                 93 - Yes - - - - - - Yes - - - - - - -
24. Baby Albert 28/M 7 TB meningitis 24 97 - - - - - - - - - - - - - - Yes - 
Sl. 
No. 
Name, Age, Sex, IP 
No. Ward 
No. of 
days 
intubated
Diagnosis Duration of 
procedure 
in min. 
Intraoperative compucations Post-operative Compucation Follow up 
     Lowest  
SaO2
Major 
Bleed
Minor 
Bleed 
False 
Passage
Resistance 
to Insertion
Trasient 
hypoten. 
Trasient 
hypoxia
Major 
bleed
Minor 
bleed
Stomal 
infec. 
Pneumo.
thorax 
Death Sub. 
emphy.
TE 
fistula
TA 
fistula
Deccanu
lated 
Tra. 
Stenosis 
638619 IMCU 
25. Nandhurayan 42/M 
640716 N1 Wd 
6 RTA with SDH 30 92 Yes - - - - - - Yes - - - - - - - - 
 
